News >

Expert Discusses CD19 CAR T-Cell Therapy in B-Cell ALL

Angelica Welch
Published: Friday, Jul 07, 2017

Eric L. Smith, MD, PhD

Eric L. Smith, MD, PhD
Chimeric antigen receptor (CAR) T-cell therapy has demonstrated responses in various hematologic malignancies, particularly B-cell acute lymphoblastic leukemia (ALL).

at the 2017 European Hematology Association Congress, Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discussed the response to CD19 CAR T-cell therapy in B-cell ALL.

OncLive: Could you please provide an overview of this study?

Smith: We, like other institutions, take a patient’s own T cells and then we engineer into those T cells a gene that on the outside has an antibody fragment that attracts the T cell to the CD19 molecule. Outside the T cell there are stimulatory signals that cause the T cell to both kill and also, equally important, to divide. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
Publication Bottom Border
Border Publication